Drugs Made In America Acquisition (DMAAR) Cash from Financing Activities (2025)

Drugs Made In America Acquisition (DMAAR) posted Cash from Financing Activities of $130600.0 for Q4 2025, up 133.2% on a QoQ basis from $56003.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAR) Cash from Financing Activities (2025) Analysis & Trends

Drugs Made In America Acquisition's Cash from Financing Activities history runs 1 years deep, the most recent figure standing at $130600.0 for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A year-over-year to $130600.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $231.7 million (changed N/A YoY) and the FY2025 annual result came in at $231.7 million, up 133351.97% from the prior year.
  • Cash from Financing Activities was $130600.0 for Q4 2025 at Drugs Made In America Acquisition, up from $56003.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $231.4 million in Q1 2025 and bottomed at $56003.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 SIM Acquisition Corp. I 314.52 Mn 314.52 Mn - 702,262.00
2 Thayer Ventures Acquisition 208.29 Mn 208.29 Mn - -
3 Newbury Street II Acquisition 185.26 Mn 185.26 Mn - -
4 Dynamix 178.78 Mn 178.78 Mn - 168,553.00
5 Hallmark Venture 103.01 Mn 102.76 Mn - 57,641.00
6 Voyager Acquisition 99.58 Mn 99.45 Mn - -
7 Gores Holdings X 95.80 Mn 95.37 Mn - -
8 Archimedes Tech SPAC Partners 89.88 Mn 89.88 Mn - -1,278.00
9 Cohen Circle Acquisition 80.05 Mn 80.05 Mn - -
10 Drugs Made In America Acquisition 1.46 Mn 1.46 Mn - 130,600.00

Historic Data

Download Data
DateValue
Dec 31, 2025 130,600.00
Dec 31, 2025 130,600.00
Sep 30, 2025 56,003.00
Sep 30, 2025 56,003.00
Jun 30, 2025 106,554.00
Jun 30, 2025 106,554.00
Mar 31, 2025 231.40 Mn
Mar 31, 2025 231.40 Mn